A randomized, open-label, multicenter, phase 2 trial assessing the efficacy and safety of apatinib combined with docetaxel and platinum as neoadjuvant treatment for triple-negative/HER2-positive breast cancer
Latest Information Update: 25 Jan 2021
At a glance
- Drugs Rivoceranib (Primary) ; Carboplatin; Cisplatin; Docetaxel; Lobaplatin; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 11 Dec 2020 Primary endpoint has been met. (pathological complete response (pCR))
- 11 Dec 2020 Results presented at the 43rd Annual San Antonio Breast Cancer Symposium
- 20 Jan 2020 New trial record